Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

British Land secures approval to redevelop Euston Tower

(Sharecast News) - Real estate developer British Land has been given the green light to redevelop the 31-storey Euston Tower into 560,000 square feet of workspaces and hospitality venues. The tower, originally completed in 1970, is located at its Regent's Place campus on Euston Road, an area home to a growing tech ecosystem.

The revised plans will retain 31% of the original structure but using a circular economy approach, cutting embodied carbon and creating a "building fit for the future".

The tower will comprise new workspaces across its 19,000 sq ft floors, 4,000 sq ft of restaurants and cafe spaces, with terraces overlooking a revamped public realm, as well as 8,000 sq ft of "enterprise space local entrepreneurs, start-ups and inclusive innovation", British Land said.

"We are delighted to receive planning consent for this incredible scheme - the first West End tower in a generation, and likely to be the last. This world-class building will provide the space for UK's greatest minds to turn research into real-world solutions," said British Land's head of development, David Lockyer.

"The tower is ideally located at our Regent's Place campus, where the Knowledge Quarter meets the West End, and where businesses can benefit from the great concentration of academic and research institutions between Harley Street and King's Cross."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.